...
首页> 外文期刊>International Journal of Cardiology >Periprocedural platelet inhibition with cangrelor in P2Y(12)-inhibitor naive patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients
【24h】

Periprocedural platelet inhibition with cangrelor in P2Y(12)-inhibitor naive patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients

机译:Cangrelor在患有急性冠脉综合征的P2Y(12)抑制剂初治患者中对围手术期血小板的抑制作用-实际患者中匹配对照的药效学比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Effective inhibition of platelet aggregation during PCI in high risk patients with ACS is of utmost importance. The new intravenous short acting P2Y(12)-receptor inhibitor cangrelor is available for use in PCI-treated patients. We aimed to study platelet inhibition during treatment with cangrelor and transition phase with oral P2Y12-receptor inhibitors in patients with acute coronary syndromes (ACS).
机译:背景:在ACS的高危患者中有效抑制PCI期间的血小板聚集至关重要。新型静脉短效P2Y(12)-受体抑制剂cangrelor可用于PCI治疗的患者。我们旨在研究急性冠状动脉综合征(ACS)患者口服坎格雷洛和过渡期口服P2Y12受体抑制剂对血小板的抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号